Recent 8-K filings for CPHI
Highest-materiality recent filing
China Pharma terminates auditor BF Borgers after SEC denies its practice privilege; appoints Enrome LLP
- SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
- China Pharma terminated Borgers as independent auditor on May 7, 2024, with audit committee approval.
-
China Pharma prices $5M registered direct offering of 2.5M shares at $2/share
Gross proceeds of $5M from sale of 2.5M shares at $2.00 per share.
-
CPHI subsidiary acquires patent for $6.93M via stock; issues 12.6M shares
Hainan Helpson acquires patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang.
-
China Pharma Holdings acquires topiroxostat nanoemulsion patent for $8.82M in stock
Transfer price of $8.82M paid in 12.6M restricted shares at $0.70/share; closing by Feb 20, 2026.
-
China Pharma Holdings shareholders approve reverse stock split up to 1:20 at annual meeting
Elected independent directors Gene Michael Bennett, Yingwen Zhang, Baowen Dong (3,500,418+ votes for each).
-
China Pharma subsidiary acquires Ipragliflozin patent for $9.8M in stock
Hainan Helpson enters Technology Transfer Agreement to acquire Ipragliflozin tablet patent from Juan Zhang.
-
China Pharma subsidiary to acquire captopril microcapsule patent for $6.3M in stock
Hainan Helpson subsidiary to receive Captopril microcapsule invention patent and preparation method from Lijie Tang.
-
China Pharma Holdings announces 1-for-10 reverse stock split effective April 15, 2025
Reverse stock split at ratio 1:10, effective April 15, 2025, trading to begin on split-adjusted basis.
-
China Pharma shareholders approve reverse stock split at 1:10–1:20; all directors elected
All five director nominees elected: Zhilin Li, Heung Mei Tsui (non-independent), Gene Michael Bennett, Yingwen Zhang, Baowen Dong (independent).
-
China Pharma rescinds Dec 12 securities purchase agreement; deal void ab initio
On Dec 23, 2024, company and an unnamed investor agreed to rescind the Dec 12 securities purchase agreement.
-
China Pharma enters into up to $600,000 at-the-market equity offering with institutional investor
SPA signed Dec 12, 2024 for up to $600K of common stock at market price, floor $0.15.
-
China Pharma extends convertible note maturity to Aug. 2025; minimum monthly payment cut 75%
Maturity date of $557,735 convertible note (Streeterville Capital) extended to August 19, 2025.
-
SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
-
China Pharma regains NYSE American compliance after reverse stock split
Received NYSE American notice on March 27, 2024 confirming compliance with continued listing standards.
-
China Pharma announces 1-for-5 reverse stock split effective March 6, 2024
Reverse split at 1-for-5 ratio, effective March 6, 2024; every 5 pre-split shares convert to 1 post-split share.
-
China Pharma subsidiary acquires psoriasis patent for $1.5M in stock
Helpson, a wholly owned subsidiary of China Pharma, entered a Technology Transfer Agreement with Lihua Li to acquire an invention patent for a psoriasis treatment.
-
China Pharma acquires COPD drug patent for $1.65M in restricted stock; royalty of 15% net profit
Subsidiary Helpson enters Technology Transfer Agreement with Tao Liu for a COPD drug combination patent.
-
China Pharma shareholders OK reverse split up to 1:10; NYSE compliance partially restored
Shareholders re-elected directors Bennett, Zhang, Dong; approved amendment to 2010 long-term incentive plan.
-
NYSE American warns China Pharma of delisting; avg price below $0.20, cure by March 2024
On Sep 27, 2023, NYSE American notified CPHI of noncompliance: 30-day avg stock price below $0.20.
-
China Pharma Holdings extends convertible note maturity to May 2024 with Streeterville Capital
Maturity extended from November 2021 note to May 19, 2024, with an extension fee of 2% of the outstanding balance.
-
Resolved low selling price deficiency via 1-for-10 reverse stock split on March 6, 2023.
-
China Pharma Holdings announces 1-for-10 reverse stock split effective March 6, 2023
Reverse stock split at 1-for-10 ratio, effective March 6, 2023, trading begins on split-adjusted basis at market open.
-
Reverse stock split at ratio up to 1:10 approved with 30,927,745 votes for, 325,290 against.
-
China Pharma receives NYSE American deficiency notice for equity shortfall
Stockholders' equity of $2.8M as of Sept 30, 2022 below the $4.0M minimum required by Section 1003(a)(ii).
-
China Pharma subsidiary acquires ophthalmic oxygen therapy patent rights for $2.1M in stock
Hainan Helpson acquires utility model patent (ZL 2022 2 0394857.6) and invention patent application for ophthalmic oxygen enriched atomization device from Chengdu Bonier.
-
Average stock price below $0.20 over 30 days as of Sept 22, 2022 triggers continued listing noncompliance.
-
CPHI receives NYSE American delisting notice for insufficient stockholders' equity
Stockholders' equity was $5.3M as of March 31, 2022, below the $6.0M minimum required under Section 1003(a)(iii).
-
Annual meeting elects five directors, approves incentive plan amendment
Quorum of 55% (35,348,061 shares) present at Dec 26, 2021 annual meeting.
-
Issued unsecured convertible promissory note for $5.25M principal ($5M net proceeds after $250K OID) to Streeterville Capital.
-
China Pharma issues 1.76M shares to CEO to offset accrued compensation; grants option to director
Compensation Committee approved 1,760,000 shares to CEO Zhilin Li at $0.67/share to partially offset $1,666,706 in accrued unpaid cash compensation.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event other_material